Say 'No to Numb' with the only Dental Anesthesia Reversal Agent

LANCASTER, Pa., June 5, 2013 /PRNewswire/ -- Dental patients hate leaving the dentist still feeling numb, and for some the lingering effects could disrupt their daily activities.

• For busy people, precious time can be hindered by the impaired ability to eat, drink and speak normally. Returning to their jobs or daily activities can be delayed after a visit to the dentist.
• Children can chew on their numb lips and cheeks causing oral hematomas.
• Diabetics may lose the ability to maintain their insulin levels by not being able to eat following a procedure.

(Photo: http://photos.prnewswire.com/prnh/20130605/PH26195-a )
(Logo: http://photos.prnewswire.com/prnh/20130605/PH26195LOGO-b )

OraVerse (Phentolamine Mesylate) is the first and only product to rapidly reverse the lingering numbness of the lip and tongue from local dental anesthetic. OraVerse cuts the patient's time being numb in half. It is administered by the dentist immediately following routine procedures such as a filling or crown prep, so the patient can return to their normal routine faster.

To find out more about OraVerse visit www.OraVerse.com. The website also allows viewers to enter their ZIP code to find a local dentist that offers OraVerse. Note: OraVerse is not recommended for use in children less than 6 years of age or weighing less than 33 pounds.

About OraVerse®
OraVerse is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used. OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years old or weighing less than 15 kg (33 lbs). In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information – for details go to www.oraverse.com. 

SOURCE Septodont